Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 7/20 | 0.38 |
| ▸ | AXL | P30530 | 8/20 | 0.37 |
| ▸ | MERTK | Q12866 | 8/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274737 | 1.00 | IRAK1 (0.38) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL2364333 | 1.00 | IRAK1 (0.38) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL2264457 | 0.91 | AXL (0.34) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL2266939 | 0.91 | FGFR1 (0.40) | IRAK1AXLMERTKIRAK4FGFR1 | |
| SCHEMBL13274930 | 0.90 | AXL (0.35) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL13274931 | 0.90 | AXL (0.35) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL13274932 | 0.90 | AXL (0.35) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL2364945 | 0.89 | FGFR1 (0.39) | IRAK1AXLMERTKIRAK4FGFR1 | |
| SCHEMBL13275028 | 0.88 | IRAK1 (0.39) | IRAK1AXLMERTKTYRO3IRAK4 | |
| SCHEMBL13274623 | 0.88 | IRAK1 (0.39) | IRAK1AXLMERTKTYRO3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | IRAK1 584/4885AXL 426/4885MERTK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.